APA (7th ed.) Citation

Stanek, J., Swearingen, B., Gabriel, H., Strittmatter, W., Chamberlain, S., & Didsbury, J. (2022). The PIONEER Study: A Multi‐center, Randomized, Double‐blind, Placebo‐controlled Phase 2 Trial of the Effects of T3D‐959 on Safety, Cognition, Function and Plasma Biomarkers in Mild to Moderate Alzheimer’s Disease Subjects: Study Update. Alzheimer's & dementia, 18(S10), -n/a. https://doi.org/10.1002/alz.064647

Chicago Style (17th ed.) Citation

Stanek, Jessica, Blake Swearingen, Hoda Gabriel, Warren Strittmatter, Stan Chamberlain, and John Didsbury. "The PIONEER Study: A Multi‐center, Randomized, Double‐blind, Placebo‐controlled Phase 2 Trial of the Effects of T3D‐959 on Safety, Cognition, Function and Plasma Biomarkers in Mild to Moderate Alzheimer’s Disease Subjects: Study Update." Alzheimer's & Dementia 18, no. S10 (2022): -n/a. https://doi.org/10.1002/alz.064647.

MLA (9th ed.) Citation

Stanek, Jessica, et al. "The PIONEER Study: A Multi‐center, Randomized, Double‐blind, Placebo‐controlled Phase 2 Trial of the Effects of T3D‐959 on Safety, Cognition, Function and Plasma Biomarkers in Mild to Moderate Alzheimer’s Disease Subjects: Study Update." Alzheimer's & Dementia, vol. 18, no. S10, 2022, pp. -n/a, https://doi.org/10.1002/alz.064647.